New FDA guidance will ease access to MAT, new medicationsdoi:10.1002/adaw.31881KnopfAlisonWiley-BlackwellAlcoholism & Drug Abuse Weekly
Medication-assisted treatment (MAT) is a comprehensive approach that combines FDA-approved medications (currently methadone, buprenorphine, or naltrexone) with counseling and other behavioral therapies to treat patients with opioid use disorder (OUD). Regular adherence...
Buprenorphine and naloxone are used to treat adults with opioid dependence/addiction. Buprenorphine helps suppress withdrawal symptoms caused by discontinuation of opioid drugs, and naloxone reverses and blocks the effect of opioids. This combination of medications is used as...
medications-a monoclonal antibody-that can provide significant benefit to patients who have run out of HIV-1 treatment options and may be able to improve outcomes for these patients.CDER approved the first monoclonal antibody to treat certain patients with HIV-1.32%CDER identified 19 of the 59 ...
创伤性脊髓损伤(SCI)后急性住院康复(AIR)的住院时间中位数从20世纪70年代的98天缩短到2015年以来的31天。1鉴于住院时间的缩短,SCI患者迫切需要优化他们积极参与治疗的时间。据报道,脊髓损伤患者在AIR期间每周错过约2.5小时(17%)的预定治疗...